Infections Responsible for 12% of Global Cancer Cases, New Research Reveals

What Happens Next

• →Increased demand for vaccines against infection-causing agents like HPV and hepatitis leads vaccine manufacturers to scale up production.
• →Healthcare systems in low- and middle-income countries ramp up efforts to provide broader access to vaccines and treatments, impacting public health budgets.
• →Pharmaceutical companies increase investment into R&D focused on antiviral therapies as a method to prevent infection-related cancers.
• →Global health organizations prioritize funding and support for programs targeting infection-related cancer prevention in economically disadvantaged regions.

Near-term: Governments and NGOs initiate immediate campaigns to promote vaccinations for HPV and hepatitis. Long-term: Reduced incidence of infection-related cancers shifts focus in healthcare policy from treatment to preventative measures, altering healthcare spending and priorities.